AzTrials
AzTrials

Restless Legs SyndromePhase 2NCT00676403

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

A Phase 2 study testing Pregabalin in people with Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 25 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Restless Legs Syndrome
What is being tested?
Pregabalin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
137 participants
Where
25 sitesin 4 countries
Study dates
Apr 2008to Jan 2009
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Moderate to severe idiopathic RLS
  • symptoms occur predominantly in the evening
  • symptoms interfere with sleep onset or maintenance

Who cannot join

  • Any secondary RLS
  • require treatment for daytime RLS symptoms
  • symptomatic neuropathies

Trial locations and contacts

25 sites in 4 countries.

25 sites in 4 countries

United States15 sites
  • Pfizer Investigational Site

    Alexandria, Virginia, 22311

  • Pfizer Investigational Site

    Aurora, Colorado, 80012

  • Pfizer Investigational Site

    Baton Rouge, Louisiana, 70808

  • Pfizer Investigational Site

    Brandon, Florida, 33511

  • Pfizer Investigational Site

    Dallas, Texas, 75231

  • Pfizer Investigational Site

    Little Rock, Arkansas, 72205

  • Pfizer Investigational Site

    Louisville, Kentucky, 40217

  • Pfizer Investigational Site

    Macon, Georgia, 31201

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Pfizer Investigational Site

    Raleigh, North Carolina, 27607

  • Pfizer Investigational Site

    Salisbury, North Carolina, 28144

  • Pfizer Investigational Site

    San Diego, California, 92121

  • Pfizer Investigational Site

    Santa Monica, California, 90404

  • Pfizer Investigational Site

    Tuscaloosa, Alabama, 35406

  • Pfizer Investigational Site

    Winston-Salem, North Carolina, 27103

Other trials in United States

Germany7 sites
  • Pfizer Investigational Site

    Bad Saarow, 15526

  • Pfizer Investigational Site

    Berlin, 10969

  • Pfizer Investigational Site

    Göttingen, 37075

  • Pfizer Investigational Site

    Mittweida, 09648

  • Pfizer Investigational Site

    München, 80331

  • Pfizer Investigational Site

    Oldenburg, 26122

  • Pfizer Investigational Site

    Schwerin, 19053

Other trials in Germany

Austria2 sites
  • Pfizer Investigational Site

    Innsbruck, A-6020

  • Pfizer Investigational Site

    Vienna, A-1080

Other trials in Austria

Spain1 site
  • Pfizer Investigational Site

    Madrid, 28036

Other trials in Spain

About this study

Official title: Randomized, Double-Blind, 6-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

Being tested
placebo, Pregabalin
Keywords
pregabalin, RLS, efficacy, safety
Medical subject headings
Restless Legs Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • placeboDrug

    Also called Sugar pill

    Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks

  • PregabalinDrug

    Also called Lyrica, PD 0144723; CI-1008

    50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

  • PregabalinDrug

    Also called Lyrica, PD 0144723; CI-1008

    100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

  • PregabalinDrug

    Also called Lyrica, PD 0144723; CI-1008

    150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

  • PregabalinDrug

    Also called Lyrica, PD 0144723; CI-1008

    300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

  • PregabalinDrug

    Also called Lyrica, PD 0144723; CI-1008

    450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

Study groups in NCT00676403
Study groupRoleWhat they receive
1Placebo comparatorPlacebo
Receives: Drug: placebo
2Experimentalinvestigational treatment
Receives: Drug: Pregabalin
3Experimentalinvestigational treatment
Receives: Drug: Pregabalin
4Experimentalinvestigational treatment
Receives: Drug: Pregabalin
5Experimentalinvestigational treatment
Receives: Drug: Pregabalin
6Experimentalinvestigational treatment
Receives: Drug: Pregabalin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6

    IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 6

Secondary outcomes (19)
  1. Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)

    Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.

    Measured: Week 6

  2. Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)

    CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

    Measured: Baseline, Week 1, Week 2, Week 4, Week 6, Last Observation Carried Forward (LOCF)

  3. Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep [in minutes]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  4. Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  5. Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  6. Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  7. Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  8. Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 4, Week 6

  9. Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 4, Week 6

  10. Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 4, Week 6

  11. Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 4, Week 6

  12. Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline,, Week 1, Week 2, Week 4, Week 6

  13. Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline,, Week 1, Week 2, Week 4, Week 6

  14. Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 4, Week 6

  15. Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 1, Week 2, Week 4, Week 6

  16. Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.

    Measured: Week 1, Week 2, Week 4, Week 6

  17. Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6

    RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 6

  18. Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.

    Measured: Baseline, Week 6

  19. Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.

    Measured: Baseline, Week 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2008 (estimated)
  2. Study startApr 2008
  3. Primary completionJan 2009
  4. Study completionJan 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
137 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00676403
Sponsor's protocol ID
A0081183
Status last verified
Jun 2010
First submitted
8 May 2008
Last updated
10 Feb 2021
Data monitoring committee
No

Publications

  • Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, Garcia-Borreguero D, Miceli J. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010 Jun;11(6):512-9. doi: 10.1016/j.sleep.2010.03.003. Epub 2010 May 13.

    PubMed 20466589

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Pregabalin in people with Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 25 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 25 sites in United States, Germany, Austria, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 4 Feb 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6 (time frame: Baseline, Week 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00676403, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in